NEW YORK, May 8, 2014 /PRNewswire/ -- The Law Office
of James C. Kelly is investigating
claims on behalf of investors of Chelsea Therapeutics
International, Ltd. ("Chelsea" or
the "Company") (NASDAQ: CHTP), concerning the proposed acquisition
of Chelsea by H. Lundbeck A/S
("Lundbeck"). Chelsea
shareholders seeking more information about this acquisition are
advised to contact James C. Kelly at
888.643.7517 or jkelly@jckellylaw.com.
The investigation concerns whether the Chelsea directors are breaching their
fiduciary duties by failing to adequately pursue alternatives to
the acquisition and maximize shareholder value. Under the
terms of the definitive merger agreement, Chelsea stockholders will receive $6.44 per share in exchange for each share of
Chelsea they own.
Chelsea shareholders could earn up
to an additional $1.50 per share
pursuant to certain contingent value rights ("CVRs") if certain
commercial milestones are achieved related to the commercial
performance of one of the Company's products in the period
2015-2017. If the CVRs are satisfied, the deal could be worth
$658 million.
However, some analysts have set a $12.00 per share price target for Chelsea, which is approximately 51% more than
what Chelsea shareholders are
expected to receive even assuming the CVRs are satisfied.
Moreover, the Company recently traded as high as $6.26 per share on March
19, 2014.
The Law Office of James C. Kelly
has extensive experience representing shareholders in mergers and
acquisition actions. Visit out website for additional
information at http://www.jckellylaw.com.
Attorney Advertising: Prior Results Do Not Guarantee A Similar
Outcome.
The Law Office of James C.
Kelly
244 5th Avenue, Suite K-278
New York, New York 10001
Tel: 212-920-5042
Toll Free Tel: 888-643-7517
Toll Free Fax: 888-224-2078
Email: jkelly@jckellylaw.com
Website: www.jckellylaw.com
SOURCE The Law Office of James C.
Kelly